Clinical News

Reevaluating the Use of Docusate in the Management of Constipation

July 01, 2020

Pharmacists can and must play an active role in guiding patients on the selection of laxatives which are supported by sound evidence.

Part 2: A Conversation on Remdesivir Trial Updates

June 29, 2020

Julie Ann Justo, infectious diseases clinical pharmacist and associate professor at the University of South Carolina College of Pharmacy, discusses the latest data from Gilead's trials for Remdesivir, a potential COVID-19 treatment.

Gilead Sets Price of Remdesivir for COVID-19 Treatment

June 29, 2020

In an open letter, Gilead Chairman and CEO Daniel O’Day announced the price of remdesivir treatment for COVID-19.

FDA OKs New Treatment for Seizures Associated with Dravet Syndrome

June 26, 2020

Officials with the FDA approved fenfluramine (Fintepla, Zogenix) oral solution, CIV for the treatment of seizures associated with Dravet syndrome in patients 2 years of age and older.

Barhemsys (Amisulpride) for Postoperative Nausea and Vomiting

June 22, 2020

On February 27, 2020, the FDA approved an intravenous solution of amisulpride (Barhemsys; Acacia Pharma) to treat and prevent postoperative nausea and vomiting.

Gilead Announces Plans for Pediatric COVID-19 Trial of Remdesivir

June 18, 2020

The phase 2/3 trials will evaluate remdesivir (Gilead) in pediatric patients, from newborns to adolescents, who have contracted severe COVID-19 symptoms.

Studies Reveal Positive Results for Infliximab Biosimilar

June 18, 2020

In studies presented this month at the European E-Congress of Rheumatology 2020, investigators revealed positive findings for the infliximab biosimilar CT-P13 (Inflectra, Remsima), which is developed by Celltrion of Incheon, Republic of Korea.

FDA Releases Drug Interaction Warning for Remdesivir and Hydroxychloroquine

June 15, 2020

The FDA updated its fact sheet on the co-administration of remdesivir with chloroquine phosphate or hydroxychloroquine.

Ribociclib Shows Overall Survival Benefit in Patients With Advanced Breast Cancer With Visceral Metastases

June 11, 2020

An exploratory analysis of 2 phase 3 trials evaluating ribociclib (Kisqali, Novartis) plus endocrine therapy in advanced breast cancer showed positive results.